Document is current
Any future updates will be listed below
-
Authors
Koga, Tomohiro https://orcid.org/0000-0003-2077-4428
Sato, Shuntaro
Miyamoto, Junya
Hagimori, Naoko
Kawazoe, Yurika
Arinaga, Kumiko
Fukushima, Chizu
Yamamoto, Hiroshi
Kawakami, Atsushi
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (17824542)
- License Information
-
More Information
Article History
Received: 28 July 2018
Accepted: 5 December 2018
First Online: 29 December 2018
Ethics approval and consent to participate
: The Local Ethics Committee at each site will approve the study protocol (approvals already in place shown in Additional file ). Any modifications to the protocol will be immediately communicated to all responsible authorities. All patients, or their legal representative, must give written informed consent before study. The patient or their representative will also be asked to give separate consent for a genetic sample to be taken. Consent for genetic sampling is not a prerequisite for study participation.
: Results obtained in this trial will be published in an international journal and may be presented at international scientific meetings. This will be included in the patient consent form.
: The investigational drugs (TCZ and placebo) and the TCZ drug information were provided by Chugai Pharmaceutical Co., Ltd. The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
